Daxor Corporation to Showcase Reduction in Mortality and Hospital Readmissions with BVA-100® Guided-Care at the Annual Meeting of the American College of Cardiology Expo 2019
March 13, 2019 08:30 ET
|
Daxor Corporation
NEW YORK, March 13, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
Daxor Corporation Announces Rise in Kit Sales and Files Form N-CSR For 2018
March 04, 2019 08:30 ET
|
Daxor Corporation
NEW YORK, March 04, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
Daxor Corporation Appoints Guido Manzo, Vice President of Sales
January 23, 2019 08:30 ET
|
Daxor Corporation
NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the...
New Data Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer (BVA-100) in Evaluation of Hypertension
November 13, 2018 08:30 ET
|
Daxor Corporation
NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
New Study Cites 82 Percent Mortality and 56 Percent Rehospitalization Reductions 30 Days After Therapy Guided by Daxor’s BVA-100 Blood Volume Analyzer in Acute Heart Failure Patients
October 30, 2018 08:30 ET
|
Daxor Corporation
Controlled Study of BVA-100 Published in The Journal of the American College of Cardiology – Heart Failure Showed 86 Percent Reduction in One-Year Mortality NEW YORK , Oct. 30, 2018 (GLOBE...
Daxor Corporation to Present at The MicroCap Conference on October 2, 2018
September 25, 2018 08:30 ET
|
Daxor Corporation
NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement, today announced...
New Independent Data Further Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer (BVA-100) Over Surrogate Measurements
September 17, 2018 08:30 ET
|
Daxor Corporation
NEW YORK, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
Newly Published Data Show Daxor Corporation's BVA-100 Is Superior To Formula-Based Estimates of Blood Volume In Assessing Patients With Heart Failure
August 20, 2018 08:30 ET
|
Daxor Corporation
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the...
Daxor Corporation Retains CORE IR as Investor Relations Firm of Record
May 29, 2018 08:30 ET
|
Daxor Corporation
NEW YORK, May 29, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces it...
Daxor Corporation Announces Positive New Critical Care Research Highlighting Benefit from BVA Use; Daxor Corporation to Exhibit at the American College of Cardiology 2018 Annual Meeting (NYSE MKT LLC: DXR)
March 09, 2018 11:55 ET
|
Daxor Corporation
New York, NY, March 09, 2018 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, exhibited at the 2018 Society for...